PharmaNutra S.p.A.

As of June 30, 2026, PharmaNutra S.p.A. carries a market capitalization of 839.74M, placing it among publicly traded companies globally. Its enterprise value stands at 842.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PharmaNutra S.p.A.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, PharmaNutra S.p.A. has 9.58M shares outstanding.

As of June 30, 2026, PharmaNutra S.p.A. trades at a trailing price-to-earnings ratio of 40.53. The price-to-sales ratio is 5.84, and the price-to-book ratio stands at 12.05.

As of June 30, 2026, PharmaNutra S.p.A. trades at an EV/EBITDA multiple of 24.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.79 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. PharmaNutra S.p.A. trades at an EV/FCF ratio of 50.30, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 842.83M versus a market cap of 839.74M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PharmaNutra S.p.A. maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.40, indicating elevated leverage, while an interest coverage ratio of 62.52 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PharmaNutra S.p.A. posted a return on equity (ROE) of 31.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 23.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 24.75, useful for judging operating efficiency across full business cycles. The company generates approximately 1.15M in revenue per employee across its workforce of 125.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.61 indicates how many times PharmaNutra S.p.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PharmaNutra S.p.A. recorded 10.31M in income tax expense. That works out to an effective tax rate of 33.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 30.97M, leaving 20.74M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, PharmaNutra S.p.A.'s stock has gained approximately 49.05% over the past 52 weeks. The 50-day moving average sits at 76.12, while the 200-day moving average is 77.64.

Over the twelve months ended June 30, 2026, PharmaNutra S.p.A. generated 144.07M in revenue and converted that into 20.74M in net income, yielding earnings per share of 2.16. EBITDA reached 34.95M, while operating income came in at 31.19M.

As of June 30, 2026, PharmaNutra S.p.A. holds 15.14M in cash and equivalents against 18.36M in total debt, resulting in a net debt position of 9.25M. Total book value stands at 69.67M, with working capital of 35.52M providing operational flexibility.

PharmaNutra S.p.A. produced 19.08M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.69M in capital expenditures, free cash flow totaled 16.38M - equivalent to 1.71 per share.

Over the twelve months ended June 30, 2026, PharmaNutra S.p.A. posted a gross margin of 76.02, reflecting its pricing power and cost economics. The operating margin of 21.65 and net profit margin of 14.40 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, PharmaNutra S.p.A. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.95, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmaNutra S.p.A. shareholders.

As of June 30, 2026, PharmaNutra S.p.A. has an Altman Z-Score of 12.96, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.